Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.5K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Lineage Commitment01:21

Lineage Commitment

3.5K
Commitment is the  process whereby stem cells:
3.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia.

British journal of haematology·2026
Same author

Between the classic hit and the modern sequel: transition dosing between peginterferon alfa-2a and ropeginterferon alfa-2b for myeloproliferative neoplasms.

Annals of hematology·2026
Same author

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
Same author

Impact of echocardiographic hemodynamics on outcomes among patients with polycythemia vera or essential thrombocythemia.

Cardio-oncology (London, England)·2026
Same author

MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms.

Seminars in hematology·2026
Same author

Echocardiographic high-output heart failure is associated with worse survival among patients with myelofibrosis.

Cardio-oncology (London, England)·2026

Related Experiment Video

Updated: Oct 16, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

336

Future Directions in Chronic Phase CML Treatment.

Nathalie Javidi-Sharifi1, Gabriela Hobbs2

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.

Current Hematologic Malignancy Reports
|October 14, 2021
PubMed
Summary

Emerging treatments for chronic phase chronic myeloid leukemia (CML) focus on combination therapies to deepen remission and achieve treatment-free remission. Novel tyrosine kinase inhibitors are also key for refractory CML.

Keywords:
BH3 mimeticsChronic myeloid leukemiaImmune checkpoint inhibitorInterferonLeukemia stem cellPPAR ligandTreatment-free remissionTyrosine kinase inhibitor

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.8K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K

Related Experiment Videos

Last Updated: Oct 16, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

336
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.8K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Chronic phase chronic myeloid leukemia (CML) has seen significant treatment advances.
  • Despite progress, challenges persist in deepening responses and achieving long-term treatment-free remission.

Purpose of the Study:

  • To review recent and emerging treatment paradigms for chronic phase CML.
  • To discuss novel therapies, drug combinations, and strategies for refractory disease.

Main Methods:

  • Review of scientific rationale, preclinical data, and clinical trial efforts for novel CML treatments.
  • Focus on three areas: new frontline approaches, treatment-free remission studies, and refractory disease management.

Main Results:

  • Combination therapies are being explored, including immunomodulatory approaches, targeting leukemia stem cells (e.g., venetoclax), and BCR-ABL1-intrinsic combinations (e.g., asciminib).
  • Second treatment-free remission strategies and novel tyrosine kinase inhibitors for advanced/refractory CML are under investigation.

Conclusions:

  • Emerging strategies aim to improve outcomes by deepening remission and enabling treatment-free CML management.
  • Continued development of novel therapies is crucial for patients with refractory disease and resistance mutations.